Skip to Content
Merck
CN

235989

Brij® L4

average Mn ~362

Synonym(s):

Polyethylene glycol dodecyl ether, Polyoxyethylene (4) lauryl ether

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
(C20H42O5)n
CAS Number:
9002-92-0
NACRES:
NA.21
PubChem Substance ID:
24854130
UNSPSC Code:
12161900
MDL number:
MFCD00043063

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Brij® L4, average Mn ~362

InChI

1S/C20H42O5/c1-2-3-4-5-6-7-8-9-10-11-13-22-15-17-24-19-20-25-18-16-23-14-12-21/h21H,2-20H2,1H3

SMILES string

CCCCCCCCCCCCOCCOCCOCCOCCO

InChI key

WPMWEFXCIYCJSA-UHFFFAOYSA-N

description

non-ionic

form

solid or liquid

mol wt

average Mn ~362

impurities

≤1% Water

refractive index

n20/D 1.451 (lit.)

mp

48 °C

solubility

water: insoluble

density

0.95 g/mL at 25 °C (lit.)

HLB

9

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Brij® L4 has been used:
  • as a surfactant for the synthesis of copper(I) oxide (Cu2O) spherical nanoparticles using a microemulsion technique
  • as a non-ionic surfactant for preparing reverse micelles to synthesize Pt3Co alloy nanoparticles
  • as a surfactant to enhance the efficiency of interfacial coupling of hydrophobic materials and to make hydrogel

Biochem/physiol Actions

Brij® L4 exhibits amphiphilic properties. Brij L4 contains hydrophobic and hydrophilic regions that can form micelles and disperse hydrophobic drugs into the core of micelles. This in turn enhances drug solubility. Brij L4 also elicits a strong inhibitory effect against breast cancer resistance protein (BCRP) mediated drug efflux. It inhibits Taq adsorption better when compared to other commonly used surfactants. Brij L4 supports droplet polymerase chain reaction (PCR) in picoliter reaction volumes at standard Taq concentrations.

General description

Brij® L4 is a non-ionic surfactant. It comprises an alkyl (C12) tail attached to an oxyethylene headgroup.

Legal Information

Brij is a registered trademark of Croda International PLC

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2

Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCX8039
MKCV8516
MKCQ7698
MKCL6849
MKCK4613

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Synthesis of Pt3Co alloy nanocatalyst via reverse micelle for oxygen reduction reaction in PEMFCs
Liu Z, et al.
Topics in Catalysis, 49(3), 241-250 (2008)
Copper (i) oxide nanoparticle-mediated C-C couplings for synthesis of polyphenylenediethynylenes: Evidence for a homogeneous catalytic pathway
Pary FF, et al.
Catalysis Science & Technology, 11(7), 2414-2421 (2021)
Paul Le Floch et al.
ACS applied materials & interfaces, 9(30), 25542-25552 (2017-07-12)
The emergence of stretchable electronics and its potential integration with textiles have highlighted a challenge: Textiles are wearable and washable, but electronic devices are not. Many stretchable conductors have been developed to enable wearable active textiles, but little has been
Jacomina W van den Esschert et al.
Annals of surgery, 255(2), 311-318 (2012-01-14)
To compare the safety and hypertrophy response after portal vein embolization (PVE) using 2 absorbable and 3 permanent embolization materials. Portal vein embolization is used to increase future remnant liver volume preoperatively. Application of temporary, absorbable embolization materials could be
Otte Brosjö et al.
Acta orthopaedica, 84(5), 502-505 (2013-11-01)
Recent data suggest that percutaneous sclerotherapy is a safe alternative to surgery for treatment of aneurysmal bone cysts (ABCs). We present our experience of this method. We retrospectively analyzed data from 38 consecutive patients treated with repeated injections of polidocanol.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service